Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
REVENUES:
Total revenue		$ 77,826	$ 46,766	$ 175,862	$ 117,652
OPERATING EXPENSES:
Cost of sales - product		3,839	3,971	11,771	10,809
Cost of sales - intangible amortization		200	200	599	599
Research and development, net of amounts reimbursable	[1]	39,450	31,791	123,340	82,230
Selling, general and administrative		33,692	35,617	108,356	116,918
Income (Loss) from operations		645	(24,813)	(68,204)	(92,904)
OTHER INCOME (EXPENSE):
Other (expense) income		(87)	59	(144)	21
Interest expense		(7,069)	(6,298)	(20,747)	(18,500)
Interest income		222	1,008	1,272	3,105
NET LOSS		(6,289)	(30,044)	(87,823)	(108,278)
OTHER COMPREHENSIVE LOSS:
Unrealized (loss) gain from available-for-sale debt securities		(26)	66	79	776
COMPREHENSIVE LOSS		(6,315)	(29,978)	(87,744)	(107,502)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 8)		$ (6,289)	$ (30,044)	$ (87,823)	$ (108,278)
LOSS PER SHARE:
Basic and diluted (in dollars per share)		$ (0.14)	$ (0.65)	$ (1.89)	$ (2.36)
WEIGHTED AVERAGE SHARES:
Basic and diluted (in shares)		46,493,126	46,141,217	46,395,124	45,975,691
Product revenue, net
REVENUES:
Total revenue		$ 50,412	$ 46,766	$ 148,448	$ 117,652
License revenue
REVENUES:
Total revenue		$ 27,414	$ 0	$ 27,414	$ 0

[1] Amounts reimbursable for the three and nine months ended September 30, 2020 were $15.4 million and $0 for the three and nine months ended September 30, 2019.